register

News & Trends - Pharmaceuticals

TGA to expand quality audits for medicinal cannabis

Health Industry Hub | March 16, 2020 |

Pharma News: In the coming months, the TGA will expand the number of quality audits of medicinal cannabis products imported or supplied under the Special Access Scheme (SAS) and other unapproved product access pathways.

Most medicinal cannabis products being supplied in Australia are ‘unapproved’, that is, they are not included in the Australian Register of Therapeutic Goods (ARTG), but they must still comply with relevant quality standards

Currently, the TGA is approving more than 3,000 SAS applications for medicinal cannabis each month. Unlike other products accessed through the SAS, unapproved medicinal cannabis products are usually not approved or registered overseas.

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

It is important that consumers have confidence in the quality of medicinal cannabis products. Therefore, a larger number of these medicinal cannabis products will be tested for compliance with the Therapeutic Goods Order No. 93 (Standard for Medicinal Cannabis) (TGO 93). This includes laboratory testing to check that the medicines are consistent with the statements made in their TGO 93 declaration about cannabinoid content. Importers and suppliers of medicinal cannabis products are legally responsible for declaring and ensuring conformity with TGO 93.

While manufacturers of imported unapproved medicines are not required to undergo GMP inspections or clearances unless further steps of manufacture occur in Australia, importers or suppliers of products that do not comply with applicable standards, such as TGO 93, may be subject to a range of regulatory compliance actions, including civil and criminal penalties.

Importers and suppliers of these products must also comply with the Therapeutic Goods Advertising Code. All material with information about the goods, including the label, must therefore be truthful, balanced and not misleading, and otherwise promote safe and proper use.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the Australian Pharma industry? Get the benchmark report by contacting us.

You may also like Allergan wins approval for first glaucoma implant


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.